Cannabis Use Disorder Clinical Trial
Official title:
Development of a Novel Cannabis Brief Intervention for Frequently-Using Emerging Adults: Pilot Randomized Trial
The purpose of this study is to compare two brief interventions targeting potentially problematic cannabis use in emerging adults (ages 18-25). Brief interventions are two 40-50 minute sessions separated by 1 week. Eligible emerging adults will complete a detailed cannabis assessment (biological and self-report), followed by one of the two brief interventions, and three follow-up assessments: one immediately after the second session and at 1- and 3-months post-intervention. Assignment to the brief intervention is random. Salivary samples will be collected at baseline, post-intervention, and both follow-ups, for a total of 4 samples, to be tested for tetrahydrocannabinol (THC) and cannabidiol (CBD).
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | June 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - Ages 18-25 - Self-Report report cannabis use on at least 20 days of the past 30 days. - Completion of an Intake Visit (PRO #94743) in the past 30 days - Submit a positive urine cannabinoid test during the Intake Visit Exclusion Criteria: - Currently engaged in substance use treatment for any type of substance use - Severe alcohol use disorder or presence of any substance use disorder (SUD) requiring a higher level of care - Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation - Significant risk of suicide or homicide |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Institute on Drug Abuse (NIDA) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Comprehensive Marijuana Motives Questionnaire (CMMQ) | This is a 44-item measure capturing the various reasons why the individual uses cannabis, including for enjoyment/enhancement, coping, social anxiety, sleep, celebration, boredom, conformity, expansion, and others. For each item, participants select 1 (almost never/never), 2 (some of the time), 3 (half the time), 4 (most of the time), or 5 (almost always/always). Higher average scores indicate more reasons for cannabis use / using cannabis more often for identified reasons. | Baseline, 1-month follow-up, 3-month follow-up | |
Other | Protective Behavioral Strategies - Marijuana (PBSM) | This is a 36-item measure that assesses the use of different cognitive and behavioral strategies that are intended to minimize harms or negative consequences associated with cannabis use. For each item, participants select 1 (Never), 2 (Rarely), 3 (Occasionally), 4 (Sometimes), 5 (Usually), or 6 (Always). Higher scores indicate more frequent use of strategies to reduce the risk of harm or negative consequences from cannabis use. | Baseline, 1-month follow-up, 3-month follow-up | |
Other | Consideration of Future Consequences Scale (CFCS) | This is a 12-item scale that assesses how characteristic or uncharacteristic it is for the individual to take into account the future consequences of an action or choice made in the present moment. Participants rate each item from 1 to 5: 1 (extremely uncharacteristic), 2 (somewhat uncharacteristic), 3 (uncertain), 4 (somewhat characteristic), 5 (extremely characteristic). Higher scores indicate a greater consideration of future consequences. | Baseline, 1-month follow-up, 3-month follow-up | |
Other | The Adolescent Reinforcement Survey Schedule - Substance Use Version (ARSS-SUV) | This is a 35-item assessment of day-to-day activities that individuals engage in with or without the use of substances (in this case cannabis) and the extent to which they enjoyed participating in the activity with or without substance use. For each frequency item, participants select 0 (not engaged), 1 (once a week or less), 2 (2-4 times per week), 3 (about once a day), or 4 (more than once a day). For each enjoyment item, participants select (0 (unpleasant/neutral), 1 (mildly pleasant), 2 (moderately pleasant), 3 (very pleasant), or 4 (extremely pleasant). A cross-product of frequency and enjoyment is created for each item to calculate final scores of substance-free reinforcement and substance-related reinforcement. A reinforcement ratio is then calculated for substance-free and substance-related activities by dividing each score from the sum of both scores (i.e., substance-free / (substance-free + substance-related); or substance-related / (substance-free + substance-related)). | Baseline, 1-month follow-up, 3-month follow-up | |
Primary | Timeline Followback (TLFB) | The TLFB is a calendar based assessment that is able to capture the frequency and quantity of substance use and other measurable behaviors. Responders identify anchor dates to facilitate recall of days in which substances were used. | Baseline, 1-month follow-up, 3-month follow-up | |
Secondary | Marijuana Assessment of Problems Inventory (MAPI) | This is a 23-item assessment of the frequency in which problems or negative consequences associated with cannabis use have occurred. For each item, participants select 0 times, 1-2 times, 3-5 times, 6-10 times, or 10+ times in the past month. Higher scores on this inventory indicate a higher frequency of problems or consequences experienced. | Baseline, 1-month follow-up, 3-month follow-up | |
Secondary | Mini International Neuropsychiatric Interview (MINI) Cannabis Use Disorder Module | This is a 12-item semi-structured clinician interview that assesses diagnostic symptom criteria of cannabis use disorder (CUD) from the Diagnostic and Statistical Manual 5th Edition (DSM-5). Clinicians select either 'yes' or 'no' for the presence of the symptom. | Baseline, 1-month follow-up, 3-month follow-up | |
Secondary | Oral Fluid Biospecimen Assay | This is a relatively brief objective assessment of recent cannabis use that is collected through mouth swab and is tested at Forensic Fluids Laboratory for the presence of delta-9 tetrahydrocannabinol (THC), delta-8 THC, and cannabidiol (CBD) using a cut-off of 1 nanogram/liter. | Baseline, 2-week follow-up, 1-month follow-up, 3-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT04139668 -
Vivitrol Treatment for Cannabis Use Disorder
|
Phase 2 | |
Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
Completed |
NCT03204305 -
Brain Imaging of Cannabinoid Receptors
|
Early Phase 1 | |
Completed |
NCT05005013 -
A Teleheath tDCS Approach to Decrease Cannabis Use
|
N/A | |
Recruiting |
NCT05292547 -
Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)
|
N/A | |
Completed |
NCT02932215 -
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT03430050 -
Progesterone for Cannabis Withdrawal
|
Early Phase 1 | |
Withdrawn |
NCT03629106 -
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder
|
N/A | |
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|
||
Completed |
NCT03624933 -
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
|
N/A | |
Recruiting |
NCT05836207 -
Rewards for Cannabis Abstinence-study
|
N/A | |
Not yet recruiting |
NCT06114212 -
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05855668 -
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
|
N/A | |
Recruiting |
NCT04517474 -
Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.
|
N/A | |
Recruiting |
NCT05885542 -
SCORE Emerging Adult Cannabis Use & Stress
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06085222 -
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
|
Phase 1 | |
Completed |
NCT03056482 -
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
|
Phase 4 |